147 related articles for article (PubMed ID: 11466681)
1. Significance of serum soluble Fas ligand in patients with bladder carcinoma.
Mizutani Y; Hongo F; Sato N; Ogawa O; Yoshida O; Miki T
Cancer; 2001 Jul; 92(2):287-93. PubMed ID: 11466681
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer.
Mizutani Y; Yoshida O; Ukimura O; Kawauchi A; Bonavida B; Miki T
Cancer Biother Radiopharm; 2002 Oct; 17(5):563-7. PubMed ID: 12470426
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder.
Ben Bahria-Sediki I; Chebil M; Sampaio C; Martel-Frachet V; Cherif M; Zermani R; Rammeh S; Ben Ammar Gaaied A; Bettaieb A
Urol Int; 2018; 100(4):476-484. PubMed ID: 29719304
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble Fas ligand in patients with gastric carcinoma.
Tsutsumi S; Kuwano H; Shimura T; Morinaga N; Mochiki E; Asao T
Cancer; 2000 Dec; 89(12):2560-4. PubMed ID: 11135216
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
7. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma.
Ichikura T; Majima T; Uchida T; Okura E; Ogawa T; Mochizuki H
Oncol Rep; 2001; 8(2):311-4. PubMed ID: 11182046
[TBL] [Abstract][Full Text] [Related]
8. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
[TBL] [Abstract][Full Text] [Related]
9. Serum soluble Fas ligand (sFasL) in patients with primary squamous cell carcinoma of the esophagus.
Kozlowski M; Kowalczuk O; Sulewska A; Dziegielewski P; Lapuc G; Laudanski W; Niklinska W; Chyczewski L; Niklinski J; Laudanski J
Folia Histochem Cytobiol; 2007; 45(3):199-204. PubMed ID: 17951168
[TBL] [Abstract][Full Text] [Related]
10. [Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia].
Urbaniak-Kujda D; Jaźwiec B; Tomaszewska-Toporska B; Wołowiec D; Kapelko-Słowik K; Kuliczkowski K
Pol Arch Med Wewn; 2002 Sep; 108(3):873-8. PubMed ID: 12600184
[TBL] [Abstract][Full Text] [Related]
11. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
12. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma.
Mouawad R; Khayat D; Soubrane C
Melanoma Res; 2000 Oct; 10(5):461-7. PubMed ID: 11095407
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of thymidylate synthase activity in bladder carcinoma.
Mizutani Y; Wada H; Ogawa O; Yoshida O; Fukushima M; Nonomura N; Miki T
Cancer; 2001 Aug; 92(3):510-8. PubMed ID: 11505394
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of orotate phosphoribosyltransferase activity in bladder carcinoma.
Mizutani Y; Wada H; Fukushima M; Yoshida O; Nakanishi H; Li YN; Miki T
Cancer; 2004 Feb; 100(4):723-31. PubMed ID: 14770427
[TBL] [Abstract][Full Text] [Related]
15. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism.
Wang CY; Zhong WB; Chang TC; Tsai YF
Metabolism; 2002 Jun; 51(6):769-73. PubMed ID: 12037733
[TBL] [Abstract][Full Text] [Related]
16. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer.
Owonikoko TK; Hossain MS; Bhimani C; Chen Z; Kim S; Ramalingam SS; Sun SY; Shin DM; Waller EK; Khuri FR
Cancer; 2013 Apr; 119(8):1503-11. PubMed ID: 23340930
[TBL] [Abstract][Full Text] [Related]
17. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer.
Mizutani Y; Katsuoka Y; Bonavida B
Int J Oncol; 2012 Apr; 40(4):1246-50. PubMed ID: 22218530
[TBL] [Abstract][Full Text] [Related]
18. Soluble form of fas and fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia.
Kuwano K; Kawasaki M; Maeyama T; Hagimoto N; Nakamura N; Shirakawa K; Hara N
Chest; 2000 Aug; 118(2):451-8. PubMed ID: 10936140
[TBL] [Abstract][Full Text] [Related]
19. Increased circulating levels of soluble Fas ligand are correlated with disease activity in patients with fibrosing lung diseases.
Kuwano K; Maeyama T; Inoshima I; Ninomiya K; Hagimoto N; Yoshimi M; Fujita M; Nakamura N; Shirakawa K; Hara N
Respirology; 2002 Mar; 7(1):15-21. PubMed ID: 11896896
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of soluble Fas ligand in cachexic patients with COPD are higher than those in non-cachexic patients with COPD.
Takabatake N; Arao T; Sata M; Inoue S; Abe S; Shibata Y; Kubota I
Intern Med; 2005 Nov; 44(11):1137-43. PubMed ID: 16357450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
